Trial Profile
Pharmacokinetic-Pharmacodynamic Modeling Study of the Reversal of Opioid-induced Respiratory Depression by the BK-channel Blocker GAL021
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Mar 2015
Price :
$35
*
At a glance
- Drugs GAL 021 (Primary)
- Indications Respiratory insufficiency
- Focus Pharmacodynamics; Pharmacokinetics; Proof of concept; Therapeutic Use
- 20 Mar 2015 New trial record